James Noble

James Noble

Chairman of the Board of Directors

Chairman of the Board of Directors since 2020.

M.A. from the University of Oxford.

Other appointments:

Chairman of the Board of Pneumagen Ltd, Ingenox Therapeutics, and another private UK-based cancer research company. Board member of Lava Therapeutics.

Previous appointments:

Co-founder and CEO of Adaptimmune and Immunocore. Board member and Deputy Chairman of GW Pharmaceuticals until its acquisition by Jazz Pharmaceuticals. Chairman and CEO of Avidex, which was acquired by Medigene. Other positions as Board member include companies, such as Medigene, PowderJect Pharmaceuticals and CuraGen Corporation.

Holds 28,000 shares, and bonds of a nominal value of SEK 2,500,000.1

Independent in relation to Orexo, its management and the company’s largest shareholders.

 


Staffan Lindstrand

Staffan Lindstrand

Board member

Board member since 2002.

M.Sc. in Engineering.

Other appointments:

Partner of HealthCap since 1997, Board member of HealthCap AB, Doctrin AB, Elsa Science AB, GET.ON Institut für Online Gesundheitstrainings GmbH, and The Swedish Association of Exchange-listed companies.

Previous appointments:

Ten years in investment banking.

Holds 26 933 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


Robin Evers

Robin Evers

Board member

Board member since 2023.

Management Studies at University of Reading and a BSc. in Molecular Biology from University of Portmouth.

Other appointments: 

Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S.

Previous appointments:

Prior to his current position, Evers has held similar senior leading position within pharmaceutical development at Novo Nordisk since 2013. Among others, Evers has also served as Vice President, Worldwide Safety & Regulatory at Pfizer Inc. and as Vice President and Head of Global Regulatory Affairs for Europe, Middle East & Africa at Wyeth Pharmaceuticals. Combined Evers has more than 25 years of experience in the pharmaceutical industry, with expertise in the development of biologics, vaccines, and small molecule drugs.

Does not hold any shares in Orexo.1

Independent in relation to Orexo and its management, but dependent in relation to the company’s largest shareholders.


Charlotte Hansson

Charlotte Hansson

Board member

Board member since 2020.

MSc. in Business Administration from Handelshögskolan at the University of Gothenburg.

Other appointments:

CFO at Tele 2 AB.

Previous appointments:

CFO at Systembolaget AB, CFO & Executive VP at Cision AB, CFO at Addici AB and various positions within business controlling at Modern Times Group.

Holds 5,500 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


Christine Rankin

Christine Rankin

Board member

Board member since 2022.

BSc. in Business Administration and Economics from Stockholm University

Other appointments:

Board member of CoinShares International Ltd, Bonesupport AB and 4C Group AB.

Previous appointments:

Board member of Adventure Box Technology AB and Technopolis Plc. SVP Corporate Control at Veoneer Inc, CFO at Cherry AB, interim CFO/Head of Finance at Serneke Group, Head of Corporate Control at Spotify and Partner/Head of the US Capital Markets group in Sweden at PwC.

Holds 2,675 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


Michael J Matly

Michael J Matly

Board member

Board member since 2022.

MBA from Harvard Business School, Medical Doctorate from Mayo Clinic College of Medicine, and Bachelor of Science from Cornell University.

Other appointments:

Co-Founder and Managing Director at 111° West Capital. 

Previous appointments:

Managing Director at Montreux Growth Partners and Director within Business Development and Investments at Mayo Clinic.

Holds 2,820 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


Mary Pat Christie

Mary Pat Christie

Board member

Board member since 2019.

MBA.

Other appointments:

Board member of Hackensack Meridian Health’s Carrier Clinic and Restaurant Technologies. 

Previous appointments:

Managing Director at Angelo Gordon & Co., where she focused on business development of new fund strategies and new strategic alliances. Prior to that at Cantor Fitzgerald as an Institutional Salesperson and was an original partner at the Seaport Group. Christie was also the founder of Mend- ham Capital Management. Her career also includes high level roles at JP Morgan, Donaldson, Lufkin & Jenrette, and Fleet Bank.

Holds 3,965 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


Fred George Wilkinson

Fred George Wilkinson

Board member

Board member since 2019

MBA., B.Sc. Pharmacy

Other appointments:

Board member of Alter Pharma Group.

Previous appointments:

Chief Executive Officer and Board member of Impax Laboratories, Inc., President of the Specialty business at Watson Pharmaceuticals, Inc. (currently Allergan), President of Duramed Pharmaceuticals, Inc., Chief Executive Officer of Columbia Laboratories, and multiple positions at Sandoz Pharmaceutical Corporation, Inc.

Holds 5,200 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


As of December 31, 2022

Nikolaj Sørensen

Nikolaj Sørensen

President and CEO

President and CEO since 2013, employed since 2011.

B.Sc., and M.Sc., Copenhagen Business School, Denmark.

Other appointments:

Member of the Board of Moberg Pharma AB and Gesynta Pharma AB.

Previous appointments:

Senior management positions at Pfizer Inc. with a focus on commercialization in Europe and Chairman of the Board and Managing Director at Pfizer AB. Prior to Pfizer management consultant at Boston Consulting Group (BCG), leading several projects within M&A, commercial transformation, and turn-arounds.

Holds 121,605 shares and stock options/share awards entitling to 362,544 shares.1


Fredrik Järrsten

Fredrik Järrsten

EVP and Chief Financial Officer

EVP and Chief Financial Officer since 2022

B.Sc. and M.Sc. majoring in Accounting and Finance at the Stockholm School of Economics, Sweden, and International Business at the University of Michigan – Stephen M. Ross School of Business, US.

Previous appointments:

CFO at Vivesto AB, 2021-June 2022. CFO and deputy Chief Executive Officer at Karolinska Development AB, 2018-2020 and as CFO at Bactiguard AB, 2014-2017. Prior to holding various positions as CFO Fredrik Järrsten served as Director Business Development at Aleris AB, 2006-2013. Additionally Fredrik Järrsten has worked as Investment Manager at Litorina Kapital and within Corporate Finance at Lazard and SEB Enskilda.

Holds 10,500 shares and stock options/share awards entitling to 103,200 shares.1


Robert A. DeLuca

Robert A. DeLuca

President Orexo US Inc.

President of Orexo US Inc. since 2013

R.Ph.

Other appointments:

 Member of the American Society of Addiction Medicine, Academy of Managed Care Pharmacy and the American and New Jersey Pharmacists Associations. Co-chair, SDHB PheoPara Coalition.

Previous appointments:

Extensive experience establishing commercial operations in the US with a combined background in market access, marketing, and sales. Has held leadership positions at multinational pharmaceutical companies including Sanofi-Aventis, Schering Plough, Berlex and Pharmacia, and most recently served as Chief Commercial Officer at Archimedes Pharmaceuticals.

Holds 8,568 shares and stock options/share awards entitling to 185,889 shares.1


Edward Kim

Edward Kim

Chief Medical Officer

Chief Medical Officer since 2022

MBA in Healthcare Management from University of Massachusetts, US, MD from Thomas Jefferson University, US and AB in Biology from Harvard University, US.

Previous appointments:

Extensive experience in medical affairs, health economics and outcomes research, and clinical development across multiple senior positions within the pharmaceutical industry. Most recently served as VP and Head of Medical Affairs at Biohaven Pharmaceuticals.  Over a decade of experience in clinical practice, academia, and hospital administration as a board-certified psychiatrist.


Robert Rönn

Robert Rönn

SVP and Head of R&D

SVP and Head of R&D since 2019, employed since 2007.

MSc in Chemical Engineering and PhD in Medicinal Chemistry, Uppsala University, Sweden.

Previous appointments:

Head of Pharmaceutical Development & IP at Orexo AB since 2016 and prior to that extensive experience
of drug discovery and development, as well as patent prosecution and litigation, from various key positions at Biolipox AB and Orexo AB.

Holds 7,121 shares and stock options/share awards entitling to 140,422 shares.1


Cecilia Coupland

Cecilia Coupland

SVP and Head of Operations

SVP and Head of Operations since 2019, employed since 2006.

MSc in Chemical Engineering, Uppsala University, Sweden.

Previous appointments:

Head of Supply Chain & Planning at Orexo since 2014 and prior to that extensive experience of global pharmaceutical manufacturing and supply chain management, as well as drug development and project management, from various key positions at AstraZeneca and Orexo AB.

Holds 11,014 shares stock options/share awards entitling to 134,699 shares.1


As of December 31, 2022

Note: Alloted long-term incentive programs with vesting terms in accordance with approval from Annual General Meeting.